Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
… Lung cancer is the leading cause of cancer deaths worldwide. Targeting the … small-cell lung
cancer (NSCLC) research, treatment, and patient outcome over the last few years. Erlotinib is …
cancer (NSCLC) research, treatment, and patient outcome over the last few years. Erlotinib is …
Reviewing the safety of erlotinib in non-small cell lung cancer
M Reck, T Mok, J Wolf, D Heigener… - … opinion on drug safety, 2011 - Taylor & Francis
… advanced pancreatic cancer. The oral administration and manageable toxicity of erlotinib,
along … : This review summarizes safety data from major clinical trials of erlotinib in patients with …
along … : This review summarizes safety data from major clinical trials of erlotinib in patients with …
Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
T Kaburagi, H Satoh, K Hayashihara… - Oncology …, 2013 - spandidos-publications.com
… efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), … erlotinib at 14 sites
(17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor …
(17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
… advanced non-small cell lung cancer. Here, we report safety and efficacy data from a
large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …
large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …
[HTML][HTML] Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study
K Kubota, Y Nishiwaki, T Tamura, K Nakagawa… - Journal of Thoracic …, 2008 - Elsevier
… The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O Merimsky, CK Cheng, JSK Au… - Oncology …, 2012 - spandidos-publications.com
… that in this analysis of elderly patients receiving erlotinib in the first-line setting, no new
safety signals were identified. The most common AE seen with erlotinib is skin rash, but this is …
safety signals were identified. The most common AE seen with erlotinib is skin rash, but this is …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
… We argue that safety could not be considered an issue, leaving … clearly demonstrate that
gefitinib is as efficacious as erlotinib. … erlotinib and gefitinib indicates gefitinib's activity and safety …
gefitinib is as efficacious as erlotinib. … erlotinib and gefitinib indicates gefitinib's activity and safety …
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
JF Lu, SM Eppler, J Wolf, M Hamilton… - Clinical …, 2006 - Wiley Online Library
… on 4068 concentration samples from 1047 patients receiving erlotinib as a single agent or in
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …
[HTML][HTML] Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib
Y Kim, SH Lee, JS Ahn, MJ Ahn… - Cancer Research and …, 2019 - synapse.koreamed.org
… Non-small cell lung cancer (NSCLC) is one of the leading causes of deaths from cancer …
inhibitors (TKIs) such as gefitinib and erlotinib have improved clinical outcomes in patients with …
inhibitors (TKIs) such as gefitinib and erlotinib have improved clinical outcomes in patients with …
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …
T Payen, J Trédaniel, L Moreau, S Larivé… - … Medicine and Research, 2021 - Elsevier
… the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations.
Using a cohort of unselected patients treated with erlotinib, we sought to further describe …
Using a cohort of unselected patients treated with erlotinib, we sought to further describe …
相关搜索
- review of erlotinib cell lung cancer
- non-small cell lung cancer
- efficacy and safety cell lung cancer
- elderly patients cell lung cancer
- japanese patients cell lung cancer
- small cell lung cancer meta analysis
- egfr mutations cell lung cancer
- phase ii study cell lung cancer
- first line erlotinib cell lung cancer
- gefitinib and erlotinib cell lung cancer
- erlotinib for treatment cell lung cancer
- erlotinib monotherapy cell lung cancer
- phase ii trial cell lung cancer
- comparison of gefitinib cell lung cancer
- previous chemotherapy cell lung cancer
- observational study cell lung cancer